Li Kang Biomedical Co Ltd (6242) - Total Liabilities
Based on the latest financial reports, Li Kang Biomedical Co Ltd (6242) has total liabilities worth NT$221.82 Million TWD (≈ $6.99 Million USD) as of December 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Also explore Li Kang Biomedical Co Ltd (6242) net asset momentum to track the company's year-over-year net asset growth rate.
Li Kang Biomedical Co Ltd - Total Liabilities Trend (2002–2025)
This chart illustrates how Li Kang Biomedical Co Ltd's total liabilities have evolved over time, based on quarterly financial data. See Li Kang Biomedical Co Ltd (6242) free cash flow to measure how efficiently the company converts operating cash flow to free cash.
Li Kang Biomedical Co Ltd Competitors by Total Liabilities
The table below lists competitors of Li Kang Biomedical Co Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
PTL LTD Ordinary Shares
NASDAQ:PTLE
|
USA | $425.73K |
|
Legacy Iron Ore Ltd
AU:LCY
|
Australia | AU$9.03 Million |
|
Unite Group PLC
LSE:UTG
|
UK | GBX1.57 Billion |
|
HS Valve Co. Ltd
KQ:039610
|
Korea | ₩37.23 Billion |
|
Corem Property Group AB (publ)
ST:CORE-A
|
Sweden | Skr38.77 Billion |
|
CORESTEM Inc
KQ:166480
|
Korea | ₩72.65 Billion |
|
Coventry Group Ltd
AU:CYG
|
Australia | AU$205.48 Million |
|
Total Soft Bank Ltd
KQ:045340
|
Korea | ₩19.09 Billion |
Liability Composition Analysis (2002–2025)
This chart breaks down Li Kang Biomedical Co Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. For the full company profile including market capitalisation, see 6242 company net worth.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.50 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.25 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.20 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Li Kang Biomedical Co Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Li Kang Biomedical Co Ltd (2002–2025)
The table below shows the annual total liabilities of Li Kang Biomedical Co Ltd from 2002 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | NT$221.82 Million ≈ $6.99 Million |
+23.28% |
| 2024-12-31 | NT$179.93 Million ≈ $5.67 Million |
-8.65% |
| 2023-12-31 | NT$196.97 Million ≈ $6.21 Million |
+65.94% |
| 2022-12-31 | NT$118.70 Million ≈ $3.74 Million |
-4.33% |
| 2021-12-31 | NT$124.07 Million ≈ $3.91 Million |
-9.08% |
| 2020-12-31 | NT$136.46 Million ≈ $4.30 Million |
-4.57% |
| 2019-12-31 | NT$143.00 Million ≈ $4.51 Million |
+0.05% |
| 2018-12-31 | NT$142.93 Million ≈ $4.50 Million |
-4.95% |
| 2017-12-31 | NT$150.38 Million ≈ $4.74 Million |
-29.72% |
| 2016-12-31 | NT$213.96 Million ≈ $6.74 Million |
-13.18% |
| 2015-12-31 | NT$246.44 Million ≈ $7.76 Million |
+154.23% |
| 2014-12-31 | NT$96.93 Million ≈ $3.05 Million |
+10.78% |
| 2013-12-31 | NT$87.50 Million ≈ $2.76 Million |
+40.12% |
| 2012-12-31 | NT$62.45 Million ≈ $1.97 Million |
+5.18% |
| 2011-12-31 | NT$59.37 Million ≈ $1.87 Million |
+19.59% |
| 2010-12-31 | NT$49.65 Million ≈ $1.56 Million |
-60.07% |
| 2009-12-31 | NT$124.35 Million ≈ $3.92 Million |
-49.77% |
| 2008-12-31 | NT$247.58 Million ≈ $7.80 Million |
-14.72% |
| 2007-12-31 | NT$290.32 Million ≈ $9.15 Million |
-46.40% |
| 2006-12-31 | NT$541.69 Million ≈ $17.07 Million |
-4.57% |
| 2005-12-31 | NT$567.66 Million ≈ $17.88 Million |
+28.17% |
| 2004-12-31 | NT$442.91 Million ≈ $13.95 Million |
+2.50% |
| 2003-12-31 | NT$432.09 Million ≈ $13.61 Million |
+3.29% |
| 2002-12-31 | NT$418.31 Million ≈ $13.18 Million |
-- |
About Li Kang Biomedical Co Ltd
Li Kang Biomedical Co., Ltd. manufactures and sells supplement, cosmeceutical, and hygienic drink products. It also engages in the management and consulting of tourism factory business; and offers telemarketing services. The company was formerly known as BAFO Technologies Corporation and changed its name to Li Kang Biomedical Co., Ltd. in September 2014. Li Kang Biomedical Co., Ltd. was founded i… Read more